Congruence Therapeutics Secures $32M Financing to Advance First-in-Class MC4R-Deficient Genetic Obesity Drug CGX-926 into Clinical Trials

September 4,Montreal, computation-driven biotechnology company Congruence Therapeutics announced the completion of a $32 million financing round. The company is building a unique pipeline of pharmacological correctors for protein misfolding diseases, including MC4R deficiency (MC4R-d) hereditary obesity, GBA1-driven Parkinson's disease, and alpha-1 antitrypsin (A1AT) deficiency. The company completed a $50 million Series A financing in 2021 and a $15 million Series A+ financing in 2023, bringing its total financing to nearly $100 million to date.

This round of financing includesWith the participation of existing investors, including: Amplitude Ventures, FSTQ, Lumira,Investissement Quebec, BDC Capital'sThrive Venture Fund, OrbiMed, Driehaus, Silver Arc andAlexandria。

Clarissa Desjardins, Ph.D., CEO of Congruence Therapeutics, stated:"This financing enables us to utilize MC4R-d driven obesityCorrective Agent Acquisition"The first clinical proof-of-concept data for a serious and debilitating disease with no current treatment options. We will also advance our programs in GBA-1 Parkinson's disease and alpha-1 antitrypsin deficiency this year to secure development candidate pipeline nominations."

Congruence Therapeutics Plans to Initiate Phase 1 Trial of CGX-926 in Healthy Volunteers by Early 2026, Including a Phase 1b Efficacy Cohort for MC4R-d Patients. Congruence Therapeutics will also advance programs targeting Parkinson’s disease and A1AT deficiency into later-stage preclinical testing.

Dr. Daniel Hétu, Managing Director of Lumira Ventures, stated:“CongruenceIs leveraging its powerful computing engine, Revenir™, to build a transformative drug pipeline. The team has demonstrated scientific rigor and capital efficiency in advancing these critical drugs into later-stage preclinical testing. We are proud to continue supporting Congruence Therapeutics as it moves its lead program, CGX-926, into clinical testing and closer to its mission of treating diseases with high unmet medical needs."

CongruenceIt continues to advance its R&D collaborations, including a multi-target deal in oncology with Ono Pharmaceuticals and another collaboration with an undisclosed pharmaceutical company on hard-to-drug metabolic targets.

Follow the official account below to explore the world with you!